… announced it would not pursue a controversial proposal to remove antidepressants as a “protected class” under … these drugs from the protected classes would have limited access to the medications needed to treat a common co-morbidity of Parkinson's disease.” Read more about …

… that physicians participate in reporting, enhance the completeness and accuracy of existing data and establish … linkages with other internal and external data sets to validate and complement NPDR data. NPDR also seeks to … and active engagement with other PD entities will enhance access to meaningful data for use in evaluating PD …

… Show” here and view his photography collection on his Web site . Christina Brdey …

… drug with analgesic and anxiolytic effects, is an opener of neuronal Kv7 potassium channels. These channels (formely known as KCNQ or M-channels) are important for … project is to examine if chronic treatment with retigabine (combined with levodopa) is effective and may delay or even …

… We have previously studied how different genetic variants associated with Parkinson’s disease (PD) affect dopamine neurons, which are the brain cells that degenerate in this disease. However, we … Cellular Phenotyping in Human iPSCS from the PPMI Cohort … Mark Cookson, PhD …

… COVID-19 vaccine updates have taken over news headlines and morning reports. … care residents. [Read more vaccine updates here . And for the most up-to-date information on COVID-19, be sure to … Vaccination for People with Parkinson’s The Advisory Committee on Immunization Practices (ACIP) is a CDC …